It is now becoming generally recognized that microarray technology will be a fundamental tool used in future genomics research. As the technology becomes more widely accessible, larger numbers of ...
Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication in the journal PLoS Medicine of groundbreaking clinical research indicating ...
With the ever-increasing density of microarrays comes a need for moresensitive and high-throughput ways to read the resulting data. Arrays contain tens of thousands of 50- to 150-μm-diameter spots per ...
Multi-center Phase I clinical study will evaluate the safety and tolerability of a monovalent strain of avian influenza A (H7N9) vaccine delivered intradermally by Vaxxas’ high-density microarray ...
The clinical study aims to evaluate a vaccine for avian influenza A (H7N9) delivered by Vaxxas’ high-density microarray patch (HD-MAP), and is funded by the United States government as a potential ...
Publication in PLoS Medicine reveals groundbreaking clinical research on broad potential of novel high-density microarray patch (HD-MAP) to efficiently deliver vaccines directly to the skin, enhancing ...
As protein arrays have become increasingly consistent and reliable, more scientists have begun to incorporate them into their proteomics experiments. Researchers are attracted by the technology’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback